183 related articles for article (PubMed ID: 10788604)
21. Methods for the use of cytokine gene-modified tumor cells in immunotherapy of cancer.
Qin Z; Blankenstein T
Methods Mol Med; 1997; 7():339-48. PubMed ID: 24493438
[TBL] [Abstract][Full Text] [Related]
22. The effect of Gd@C82(OH)22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-alpha mediated cellular immunity.
Liu Y; Jiao F; Qiu Y; Li W; Lao F; Zhou G; Sun B; Xing G; Dong J; Zhao Y; Chai Z; Chen C
Biomaterials; 2009 Aug; 30(23-24):3934-45. PubMed ID: 19403166
[TBL] [Abstract][Full Text] [Related]
23. Cytokine-induced senescence for cancer surveillance.
Wieder T; Brenner E; Braumüller H; Bischof O; Röcken M
Cancer Metastasis Rev; 2017 Jun; 36(2):357-365. PubMed ID: 28391403
[TBL] [Abstract][Full Text] [Related]
24. In vitro cytokine responses of peripheral blood mononuclear cells from healthy dogs to distemper virus, Malassezia and Toxocara.
Valli JL; Williamson A; Sharif S; Rice J; Shewen PE
Vet Immunol Immunopathol; 2010 Apr; 134(3-4):218-29. PubMed ID: 19880197
[TBL] [Abstract][Full Text] [Related]
25. Cancer immunotherapy.
Schuster M; Nechansky A; Kircheis R
Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
[TBL] [Abstract][Full Text] [Related]
26. Cells and cytokines in immunotherapy and gene therapy of cancer.
Pawelec G; Rees RC; Kiessling R; Madrigal A; Dodi A; Baxevanis C; Gambacorti-Passerini C; Masucci G; Zeuthen J
Crit Rev Oncog; 1999; 10(1-2):83-127. PubMed ID: 10327211
[TBL] [Abstract][Full Text] [Related]
27. Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib.
Kiani A; Habermann I; Schäke K; Neubauer A; Rogge L; Ehninger G
Haematologica; 2003 Jul; 88(7):754-61. PubMed ID: 12857553
[TBL] [Abstract][Full Text] [Related]
28. Cytokine and immuno-gene therapy for solid tumors.
Li CY; Huang Q; Kung HF
Cell Mol Immunol; 2005 Apr; 2(2):81-91. PubMed ID: 16191413
[TBL] [Abstract][Full Text] [Related]
29. The impact of cytokines on high dose chemotherapy followed by transplantation of purified and ex vivo expanded peripheral blood stem cells: achieving a state of minimal residual disease for tumor immunotherapy with cytokine gene transfected cells.
Mertelsmann R
Eur Cytokine Netw; 1995; 6(2):79-82. PubMed ID: 7578991
[No Abstract] [Full Text] [Related]
30. Strategies for cytokine utilisation in tumor therapy.
Di Pierro F; Cavallo F; Pericle F; Bertini S; Giovarelli M; Forni G
Med Oncol Tumor Pharmacother; 1993; 10(1-2):53-9. PubMed ID: 8258996
[TBL] [Abstract][Full Text] [Related]
31. New developments in the use of cytokines for cancer therapy.
Maini A; Morse PD; Wang CY; Jones RF; Haas GP
Anticancer Res; 1997; 17(5B):3803-8. PubMed ID: 9427784
[TBL] [Abstract][Full Text] [Related]
32. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
33. Anti-tumor immunity of BAM-SiPc-mediated vascular photodynamic therapy in a BALB/c mouse model.
Yeung HY; Lo PC; Ng DK; Fong WP
Cell Mol Immunol; 2017 Feb; 14(2):223-234. PubMed ID: 26388236
[TBL] [Abstract][Full Text] [Related]
34. Cytokine-based therapy and biochemotherapy for advanced melanoma.
Atkins MB
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2353s-2358s. PubMed ID: 16609058
[TBL] [Abstract][Full Text] [Related]
35. Nitric oxide inhibits the secretion of T-helper 1- and T-helper 2-associated cytokines in activated human T cells.
Bauer H; Jung T; Tsikas D; Stichtenoth DO; Frölich JC; Neumann C
Immunology; 1997 Feb; 90(2):205-11. PubMed ID: 9135548
[TBL] [Abstract][Full Text] [Related]
36. Cytokines and anti-cytokines as therapeutics--an update.
Tayal V; Kalra BS
Eur J Pharmacol; 2008 Jan; 579(1-3):1-12. PubMed ID: 18021769
[TBL] [Abstract][Full Text] [Related]
37. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapeutic approach for better management of cancer--role of IL-18.
Kuppala MB; Syed SB; Bandaru S; Varre S; Akka J; Mundulru HP
Asian Pac J Cancer Prev; 2012; 13(11):5353-61. PubMed ID: 23317183
[TBL] [Abstract][Full Text] [Related]
39. The effects of cytokine gene transfer into tumors on host cell infiltration and regression.
McBride WH; Economou JS; Syljuåsen RG; Parrish C; Hackman D; Latham V; Chiang CS; Dougherty GJ
Anticancer Res; 1996; 16(3A):1139-43. PubMed ID: 8702225
[TBL] [Abstract][Full Text] [Related]
40. Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.
Osada T; Morse MA; Lyerly HK; Clay TM
Int Immunol; 2005 Sep; 17(9):1143-55. PubMed ID: 16027139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
